Bayer's Debt Clock Ticks Faster Than Its Court Calendar
Published on 09/17/2026 at 07:50 | Editorial boerse-global.de
Bayer shares are idling near EUR 48.72, barely a whisker above their 50-day moving average of EUR 48.47 — a flatline that tells you almost nothing about the forces actually shaping the stock. The real action is happening off the chart, in a Missouri courtroom and on a deal calendar that has yet to deliver its promised relief.
Two clocks are running at once. One measures how quickly the German conglomerate can shrink its net financial debt, now guided down to EUR 29–30 billion for year-end 2026 from an earlier target of EUR 32–33 billion. The other tracks the glacial pace of a USD 7.25 billion settlement covering tens of thousands of claims that its Monsanto unit's glyphosate-based herbicide caused cancer. Whichever clock runs out first will likely set the share price's direction.
The Apollo Lifeline
The debt revision, announced in August, hinges on a transaction that has not yet closed. Apollo has agreed to take a minority stake in a new entity housing Bayer's long-acting contraceptive business, injecting EUR 3.0 billion of equity into the parent. Completion is penciled in for the third quarter of 2026 — which means the balance-sheet relief investors are pricing remains, for now, a promise rather than a fact.
That distinction matters. A hearing on the Roundup settlement was already held last Monday before a court in the US state of Missouri, and the shares have slipped 1.3% since. Until the judge signs off, every operational gain gets discounted for legal uncertainty.
Where the Earnings Story Actually Stands
Strip away the litigation and the pharmaceutical unit is delivering. Second-quarter 2026 revenue rose 2.2% on an adjusted basis to EUR 10.872 billion, while adjusted EBITDA advanced 1.9% to EUR 2.144 billion. Core earnings per share, though, fell 16.7% to EUR 0.95 — a reminder that special items and financing costs are eating into the operating improvement. Management nonetheless reaffirmed its full-year 2026 guidance for adjusted EBITDA of EUR 9.6–10.1 billion.
Should investors sell immediately? Or is it worth buying Bayer?
On the pipeline front, the FDA has already granted accelerated approval to Sevabertinib, marketed as Hyrnuo, as a first-line therapy for HER2-mutated non-squamous NSCLC — a confirmed regulatory milestone that bolsters the oncology franchise. Add to that the June closing of the Perfuse Therapeutics transaction for rights to PER-001, a Phase II candidate for glaucoma and diabetic retinopathy, and a picture of broadening pharma diversification emerges.
Agriculture's Quiet Counterweight
Less discussed but strategically important is the crop science division, where Bayer has now launched the first two of ten planned products, each targeting peak annual sales of at least EUR 500 million. The company reaffirmed its goal of generating more than EUR 1 billion in Clean EBITDA improvements in the segment by 2029. A commercial agreement with Finland's Neste to scale cultivation of "newgold" winter rapeseed for biofuel production adds a further plank, signaling that Bayer is hedging beyond classic crop protection into feedstocks for the energy transition.
These moves give investors something concrete to anchor on while the glyphosate overhang persists — but they are unlikely to move the needle on their own.
What the Chart Is Saying
The stock sits about 9.5% below its 52-week high of EUR 53.86, reached on July 3, 2026, yet has still built a gain of roughly 32% since the start of the year. Measured from its 52-week low of EUR 25.78 in November 2025, the advance is closer to 89%. A 30-day volatility reading of 18% and an RSI of 50.9 betray no strong directional bias — the market itself appears undecided about which scenario wins.
The bull case is straightforward: debt falls toward EUR 29–30 billion as planned, Hyrnuo-style approvals keep adding pharmaceutical substance, and the Roundup settlement clears its final judicial hurdle without major objections. Under that outcome, the shares could retest their July peak.
The bear case is equally plausible. Court approval can stall or fail, particularly if individual claimant groups object — an outcome that remains unresolved. The 16.7% drop in core EPS shows that operating progress does not automatically reach shareholders while interest and special charges weigh on margins. And the Apollo deal is not done; a delay beyond the third quarter would push back the very deleveraging that underpins the revised guidance.
Two dates will settle the argument: the next stage of the approval process before the Missouri Circuit Court, and the announced closing of the Apollo transaction within the current quarter. Until both resolve, Bayer's shares are likely to keep marking time — caught between a balance sheet healing on schedule and a legal cloud that has yet to lift.
Ad
Bayer Stock: New Analysis - 17 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
